Fasting Glucose: Sex- and Cycle-Related Differences, Normal Range, and Optimal Targets

What Is the Normal Fasting Glucose Range?

The American Diabetes Association (ADA) classifies fasting plasma glucose below 100 mg/dL as normal, 100 to 125 mg/dL as impaired fasting glucose (prediabetes), and 126 mg/dL or above as meeting a diagnostic threshold for type 2 diabetes when confirmed on a second test. The ADA 2024 Standards of Care codify these cutoffs and note that any single abnormal result requires confirmation before a diabetes diagnosis is assigned.

These cutoffs, however, are population-derived thresholds for disease detection, not targets for metabolic health. A result of 98 mg/dL technically clears the "normal" bar but may still reflect early insulin resistance, particularly in people with visceral adiposity.

Laboratory Method Matters

Fasting glucose is measured on venous plasma using enzymatic methods (hexokinase or glucose oxidase). Point-of-care fingerstick meters may read 10 to 15% lower than simultaneous venous draws due to whole-blood versus plasma differences and capillary dilution. Clinical decisions should rest on certified laboratory venous results, not home glucometers.

How Long to Fast Before the Test

The ADA and the WHO 2006 diagnostic criteria both require a minimum 8-hour fast. Most clinical labs instruct patients to fast 10 to 12 hours to reduce variability from late evening meals. Water, plain black coffee (debated, see below), and essential medications are generally permitted, but any caloric intake invalidates the fasting state.

What Is the Optimal Fasting Glucose for Longevity and Metabolic Health?

"Normal" and "optimal" diverge significantly at this lab value. Longevity medicine consensus, supported by large prospective cohort data, places the optimal fasting glucose range at 72 to 85 mg/dL.

The ARIC Study (N=15,792) found that cardiovascular event rates began rising at fasting glucose values above 85 mg/dL, well before the 100 mg/dL prediabetes threshold. Participants with fasting glucose in the 95 to 99 mg/dL range had a relative risk of incident diabetes over 10 years of approximately 2.33 compared to those below 85 mg/dL.

Why 72 to 85 mg/dL Is the Target

Fasting glucose below 72 mg/dL raises concern for reactive hypoglycemia or excess exogenous insulin effect. Above 85 mg/dL in a fasted state, beta-cell compensation is already underway in many individuals. The Whitehall II cohort study (N=6,538) demonstrated that people who later developed type 2 diabetes showed rising fasting glucose values starting 10 or more years before diagnosis, with trajectories diverging from non-progressors at around the 85 mg/dL mark.

The Gray Zone: 86 to 99 mg/dL

Patients with fasting glucose between 86 and 99 mg/dL fall into a clinical gray zone. Standard reporting calls this "normal," yet a 2010 analysis in Diabetes Care found that individuals in this range had a 49% higher 10-year risk of progressing to type 2 diabetes compared to those below 86 mg/dL, even after adjusting for BMI and family history. This is the range where lifestyle intervention, continuous glucose monitoring, and GLP-1 candidacy conversations often begin at HealthRX.

Sex-Based Differences in Fasting Glucose

Biological sex exerts a meaningful effect on fasting glucose that most standard lab reference ranges do not account for.

Men vs. Women: The Pre-Menopause Divergence

Pre-menopausal women consistently show lower fasting glucose than age- and BMI-matched men. A large cross-sectional analysis in Diabetologia (N=27,257) found that men had mean fasting glucose approximately 3 to 4 mg/dL higher than pre-menopausal women across most age brackets. This gap narrowed significantly after menopause.

The mechanism is multifactorial. Estradiol enhances insulin sensitivity in skeletal muscle via estrogen receptor alpha (ERα) signaling, as reviewed in Endocrine Reviews. Testosterone, by contrast, tends to increase hepatic glucose output at higher concentrations, which may partly explain the male-female differential.

What This Means for Interpretation

A fasting glucose of 92 mg/dL in a 35-year-old pre-menopausal woman warrants a different level of concern than the same value in a 35-year-old man. Both clear the 99 mg/dL cutoff, but the woman is operating closer to the male mean, suggesting her metabolic trajectory may already be shifting toward a higher-risk phenotype. Clinicians should contextualize FPG results against sex-specific centile distributions, not a single universal cutoff.

Postmenopause: The Gap Closes

After menopause, estradiol loss removes the insulin-sensitizing buffer. A meta-analysis in Menopause (2014) covering 32 studies found that postmenopausal women had significantly higher fasting glucose, HOMA-IR, and 2-hour post-load glucose than age-matched pre-menopausal controls. Menopausal hormone therapy (MHT) with estrogen appears to attenuate this shift: the Women's Health Initiative insulin resistance substudy showed that conjugated equine estrogen (0.625 mg/day) reduced incident type 2 diabetes by 21% compared to placebo over 5.6 years.

Menstrual Cycle Phases and Fasting Glucose Fluctuations

Women with regular menstrual cycles experience measurable shifts in fasting glucose and insulin sensitivity across cycle phases. These shifts are clinically relevant when interpreting FPG results and when timing metabolic testing.

Follicular Phase (Days 1 to 14)

The follicular phase is characterized by rising estradiol and relatively low progesterone. Insulin sensitivity is at its cycle peak during this phase. A study in the Journal of Clinical Endocrinology and Metabolism (JCEM) measuring glucose and insulin every other day across full menstrual cycles found that fasting glucose and fasting insulin were lowest in the mid-follicular phase (days 6 to 10), with mean FPG approximately 3 to 5 mg/dL lower than luteal-phase nadir values.

Ovulation Window (Days 12 to 16)

Estradiol peaks at the LH surge and then drops sharply. Progesterone begins its rise. Glucose metabolism remains relatively favorable at ovulation itself, but the transition starts here.

Luteal Phase (Days 15 to 28)

Progesterone dominates the luteal phase, and this hormone has direct anti-insulin effects. Progesterone reduces GLUT-4 translocation in skeletal muscle and increases counter-regulatory hormone activity. Valdes et al. (JCEM, 2000) documented insulin resistance indices rising by 10 to 25% in the late luteal phase compared to early follicular phase values in healthy cycling women.

Practically, a woman tested on day 22 of her cycle may show a fasting glucose 5 to 10 mg/dL higher than if tested on day 8. Neither result is wrong. Both are accurate snapshots of different hormonal states. For consistency, fasting glucose testing in cycling women is best scheduled during days 3 to 9 of the follicular phase.

Premenstrual Period (Days 24 to 28)

The late luteal phase sees progesterone decline alongside a drop in serotonin and changes in appetite regulation. Some women experience increased carbohydrate craving and higher caloric intake in this window, which may compound the progesterone-mediated insulin resistance and push next-morning fasting glucose higher than the hormonal effect alone would predict. This does not represent pathology, but it is a confounding factor in single-timepoint FPG assessment.

Testosterone, PCOS, and Fasting Glucose in Women

Elevated androgens in women, particularly free testosterone, are strongly associated with insulin resistance and higher fasting glucose independent of BMI.

PCOS as a High-Risk Phenotype

Polycystic ovary syndrome (PCOS) affects 6 to 12% of reproductive-age women by AES/PCOS Society criteria. Insulin resistance is present in 50 to 80% of women with PCOS regardless of weight. A 2016 Endocrine Society guideline statement recommends screening all women with PCOS for impaired fasting glucose and type 2 diabetes using either FPG or a 75-gram oral glucose tolerance test (OGTT), noting that FPG alone may miss up to 30% of cases of impaired glucose tolerance in this population.

Why FPG Alone Underestimates Risk in PCOS

Women with PCOS often have normal or low-normal fasting glucose but significantly elevated 1-hour and 2-hour post-load glucose. The Androgen Excess and PCOS Society has noted that an FPG below 100 mg/dL in a woman with PCOS should prompt an OGTT rather than reassurance, particularly if other insulin resistance markers (elevated fasting insulin, HOMA-IR above 2.5, waist-to-height ratio above 0.5) are present.

Testosterone Therapy in Men and Fasting Glucose

Testosterone replacement therapy (TRT) in hypogonadal men has a nuanced relationship with glucose metabolism that depends heavily on baseline adiposity and the degree of hypogonadism.

Evidence From the T-TRIALS

The Testosterone Trials (T-TRIALS) enrolled 788 men aged 65 and older with low testosterone (below 275 ng/dL) and randomized them to testosterone gel or placebo for 12 months. Fasting glucose did not change significantly as a primary endpoint. A secondary analysis, however, found that men with baseline fasting glucose in the 100 to 125 mg/dL prediabetes range showed a trend toward lower FPG at 12 months with testosterone treatment compared to placebo, consistent with testosterone's known effect on reducing visceral fat mass and increasing lean muscle.

Supraphysiologic Testosterone and Glucose

Anabolic steroid use at supraphysiologic doses (outside therapeutic ranges) shows the opposite pattern. High-dose androgens decrease insulin receptor expression and promote hepatic insulin resistance. Hobbs et al. (JCEM, 1996) showed that testosterone enanthate at 600 mg/week for 20 weeks increased fasting insulin by 22% and reduced insulin sensitivity index by 25% in healthy eugonadal men, without a proportionate rise in fasting glucose due to compensatory beta-cell up-regulation.

Progesterone, Estrogen Therapy, and Fasting Glucose in Men and Postmenopausal Women

Exogenous hormones alter fasting glucose through multiple mechanisms depending on route of administration, dose, and the individual's baseline metabolic state.

Oral vs. Transdermal Estrogen

Oral estradiol undergoes first-pass hepatic metabolism, increasing sex hormone-binding globulin (SHBG) and modifying hepatic glucose output. Transdermal estradiol bypasses first-pass metabolism. A randomized trial in Menopause (2006) found that transdermal estradiol (50 mcg/day patch) preserved insulin sensitivity better than oral conjugated estrogen at 6 months, with fasting glucose stable in the transdermal group versus a modest 2 to 3 mg/dL rise in the oral group.

Progestogens: Not All Equal

Synthetic progestins (medroxyprogesterone acetate, norethindrone acetate) have more pronounced anti-insulin effects than micronized progesterone. The PEPI trial (N=875) demonstrated that women receiving conjugated estrogen plus medroxyprogesterone acetate had greater deterioration in insulin sensitivity than those receiving estrogen plus micronized progesterone over 3 years, with corresponding differences in fasting glucose trajectory. For women at elevated metabolic risk, the choice of progestogen is not cosmetic: it carries measurable glucose consequences.

GLP-1 Candidacy and Fasting Glucose as a Baseline Lab

At HealthRX, fasting glucose is a required baseline for all GLP-1 agonist prescriptions. It classifies patients into metabolic phenotypes that guide starting dose, titration pace, and monitoring frequency.

Interpreting FPG in the GLP-1 Context

Semaglutide 2.4 mg (Wegovy) in the STEP-1 trial (N=1,961) reduced fasting glucose from a mean baseline of 99.2 mg/dL to 91.8 mg/dL at 68 weeks in the treatment group, compared to a change from 99.0 to 97.0 mg/dL in placebo. The between-group difference was 5.5 mg/dL (P<0.001). The trial enrolled people with BMI 30 or above, or BMI 27 with at least one weight-related comorbidity, without diabetes, which is why baseline FPG was clustered near the high-normal range.

Tirzepatide and Fasting Glucose

In the SURMOUNT-1 trial (N=2,539), tirzepatide 15 mg reduced fasting glucose by a mean of 17.5 mg/dL from baseline over 72 weeks in non-diabetic participants with obesity, representing a shift from 104.8 mg/dL to 87.3 mg/dL. This magnitude of reduction, exceeding semaglutide's effect in comparable populations, aligns with tirzepatide's dual GIP/GLP-1 mechanism and its stronger effect on hepatic glucose production.

A baseline FPG at or above 100 mg/dL in a GLP-1 candidate indicates that glycemic benefit, not just weight reduction, should be tracked as a treatment outcome.

How to Minimize Fasting Glucose Variability Before Testing

Single-timepoint FPG carries meaningful intra-individual variability. Sacks et al. (Clinical Chemistry, 2002) estimated the biological coefficient of variation (CV) for FPG at approximately 5.7%, meaning a true value of 90 mg/dL may produce results ranging from 85 to 95 mg/dL on repeat testing under identical conditions.

To reduce variability:

• Fast for 10 to 12 hours, not just 8.
• Avoid strenuous exercise in the 24 hours before the draw. A single bout of high-intensity interval training can deplete glycogen and lower next-morning FPG by 4 to 8 mg/dL, which may mask impaired fasting glucose.
• Test in the follicular phase if cycle-phase timing is feasible.
• Avoid acute illness, which raises cortisol and drives stress hyperglycemia even in people without diabetes.
• If a result is borderline (95 to 105 mg/dL), repeat the test on a separate day before acting on it.

Reading Your Fasting Glucose Result: A Practical Interpretation Guide

| FPG (mg/dL) | Classification | Clinical Action | |---|---|---| | Below 72 | Low-normal or hypoglycemia risk | Evaluate for reactive hypoglycemia, review medications | | 72 to 85 | Optimal metabolic range | Maintain with lifestyle | | 86 to 99 | High-normal, gray zone | Lifestyle review, HOMA-IR, consider CGM | | 100 to 125 | Impaired fasting glucose (prediabetes) | Formal risk assessment, GLP-1 candidacy evaluation | | 126 or above | Diabetes threshold (confirm on second test) | Immediate clinical referral |

For women in the luteal phase or on synthetic progestins, consider adding 3 to 5 mg/dL of tolerance before escalating clinical concern in the 86 to 99 range.